<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134374">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01745679</url>
  </required_header>
  <id_info>
    <org_study_id>RC12-0171</org_study_id>
    <nct_id>NCT01745679</nct_id>
  </id_info>
  <brief_title>Pharmacological Study of High Doses of Ceftriaxone in Meningitidis</brief_title>
  <official_title>Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France:ANSM</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to describe the concentrations of Ceftriaxone at the steady state,
      in patients treated for meningitis, to determine pharmacokinetic parameters at high dose  in
      this population. Additionally, we aimed to detect adverse effect, especially neurological
      trouble related to Ceftriaxone toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Day 0 : onset of treatment by Ceftriaxone, following usual therapeutic process (French
      Guideline) From Day 0 to Day 4 : inclusion, clinical and biological data collection,
      electroencephalogram at baseline.

      Two samples for ceftriaxone concentration monitoring :

        -  Trough concentration of ceftriaxone at steady state

        -  A random sample (population PK) At the end of ceftriaxone treatment : assessment of
           tolerance and efficacy of the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>plasmatic concentration of ceftriaxone, measured at the steady state (after 48 hours of treatment at least).</measure>
    <time_frame>after at least 48 hours of ceftriaxone treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological troubles</measure>
    <time_frame>participants will be followed for the duration of ceftriaxone treatment, an expected average of two weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Neurological troubles explored by electroencephalogram aiming to diagnose epileptic syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical evolution</measure>
    <time_frame>participants will be followed for the duration of ceftriaxone treatment, an expected average of 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time of return to apyrexia, health complications and lenght of hospital stay   will be registered.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Meningitis</condition>
  <condition>Neurological Infections</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ceftriaxone will be administered à high dose : &gt; or equal to 75mg/kg/day or 4 gr/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone treatment</intervention_name>
    <description>ceftriaxone will be administered à high dose : &gt; or equal to 75mg/kg/day or 4 gr/day</description>
    <arm_group_label>Ceftriaxone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized adults patients,

          -  age equal or above 18

          -  Patients with Community or surgical acquired neurological infections, meningitis and
             others

          -  Prescription of ceftriaxone &gt;75mg/kg/d or &gt;4g/d -

          -  Subjects affiliated to French health insurance (social security)

          -  Informed consent form signed

        Exclusion Criteria:

        - Patient under guardianship
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathalie ASSERAY, PH</last_name>
    <phone>+33 2 40 08 33 16</phone>
    <email>nasseray@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>dominique NAVAS, PH</last_name>
    <phone>+33 2 40 08 41 54</phone>
    <email>dominique.navas@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nantes Universitary Hospital</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie ASSERAY, PH</last_name>
      <phone>+33 2 40 08 33 16</phone>
      <email>nasseray@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie ASSERAY, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angers Universitary Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre PiAbgueguen, PH</last_name>
      <email>PiAbgueguen@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre ABGUEGUEN, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Roche/Yon hospital</name>
      <address>
        <city>La Roche/Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GUIMARD, PH</last_name>
      <email>thomas.guimard@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas GUIMARD, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poitiers Universitary hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>France ROBLOT, PU-PH</last_name>
      <email>f.roblot@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>France ROBLOT, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes Universitary hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre TATTEVIN, PH</last_name>
      <phone>+33 2 99 28 43 21</phone>
      <email>pierre.tattevin@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre TATTEVIN, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Nazaire hospital</name>
      <address>
        <city>St Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme HOFF, PH</last_name>
      <email>j.hoff@ch-saintnazaire.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme HOFF, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours universitary hospital</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis BERNARD, PU-PH</last_name>
      <email>garot@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Louis BERNARD, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>December 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ceftriaxone</keyword>
  <keyword>Adverse drug effects</keyword>
  <keyword>Therapeutic monitoring</keyword>
  <keyword>Meningitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
